CXCR4-using (X4) human immunodeficiency virus type 1 (HIV-1) variants evolve from CCR5-using (R5) variants relatively late in the natural course of infection in 50% of HIV-1 subtype B-infected individuals and subsequently coexist with R5 HIV-1 variants. This relatively late appearance of X4 HIV-1 variants is poorly understood. Here we tested the neutralization sensitivity for soluble CD4 (sCD4) and the broadly neutralizing antibodies IgG1b12, 2F5, 4E10, and 2G12 of multiple coexisting clonal R5 and (R5)X4 (combined term for monotropic X4 and dualtropic R5X4 viruses) HIV-1 variants that were obtained at two time points after the first appearance of X4 variants in five participants of the Amsterdam Cohort Studies on HIV-1 infection and AIDS. Recently emerged (R5)X4 viruses were significantly more sensitive to neutralization by the CD4-bindingsite-directed agents sCD4 and IgG1b12 than their coexisting R5 viruses. This difference was less pronounced at the later time point. Early (R5)X4 variants from two out of four patients were also highly sensitive to neutralization by autologous serum (50% inhibition at serum dilutions of >200). Late (R5)X4 viruses from these two patients were neutralized at lower serum dilutions, which suggested escape of X4 variants from humoral immunity. Autologous neutralization of coexisting R5 and (R5)X4 variants was not observed in the other patients. In conclusion, the increased neutralization sensitivity of HIV-1 variants during the transition from CCR5 usage to CXCR4 usage may imply an inhibitory role for humoral immunity in HIV-1 phenotype evolution in some patients, thus potentially contributing to the late emergence of X4 variants.Entry of human immunodeficiency virus type 1 (HIV-1) into a host cell is mediated by binding of the viral envelope glycoprotein 120 (gp120) to CD4 and a coreceptor, of which CCR5 and CXCR4 are the most important on primary cells (7,8,9). Primary HIV-1 infections are generally established by R5 viruses, which remain present throughout the course of infection (27). In approximately 50% of therapy-naive individuals infected with subtype B HIV-1, X4 viruses evolve from R5 variants, preceding an increased CD4 ϩ T-cell decline and accelerated progression to AIDS (4,24,27,30).The relatively late appearance of X4 HIV-1 variants is poorly understood. R5 and X4 subtype B HIV-1 variants can genetically be distinguished by the absence or presence of a positively charged amino acid on positions 11 and/or 25 in the third variable loop (V3) of the gp120 envelope (10). In vitro experiments revealed that these mutations in V3 (6), as well as other single or double mutations in V3 and other domains of gp120 (2, 12), are sufficient to change coreceptor usage. However, in spite of the high mutation rate of HIV-1, X4 viruses do not evolve rapidly in vivo and not in all infected patients. Moreover, the earliest detectable X4 variants in vivo show more than only one or two amino acid substitutions compared to coexisting R5 variants (16), suggestive of compensatory mutations. The...